{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-005619","form_type":"8-K","ticker":"QNRX","cik":"0001671502","company_name":"Quoin Pharmaceuticals, Ltd.","filed_at":"2025-01-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.385121+00:00","generated_at":"2026-05-27T14:35:28.731765+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Quoin reports reversal of QRX003 benefits 4 weeks post-discontinuation in Netherton syndrome study","bullets":["M-IASI score returned from 3 (12 weeks) to 18 at 4 weeks post-discontinuation, equaling baseline of 18.","WINRS (itch) worsened from 2 at 12 weeks to 8 post-discontinuation, exceeding baseline of 7.","IGA regressed from 'Almost Clear' at 12 weeks back to 'Moderate', same as baseline.","Data from first twice-daily dosed subject shows complete reversal of all clinical improvements after stopping QRX003."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-005619","json":"https://secwatch.observer/filing/0001104659-25-005619.json","markdown":"https://secwatch.observer/filing/0001104659-25-005619.md","text":"https://secwatch.observer/filing/0001104659-25-005619.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671502/000110465925005619/0001104659-25-005619-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671502/000110465925005619/tm254263d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T14:35:28.731765+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}